A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Complement 1, a health tech startup transforming cancer care through personalized lifestyle medicine, today announced a $16 million oversubscribed seed ...
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Complement 1, a pioneering health technology company transforming cancer care through evidence-based lifestyle modification, today announced the appointment ...
MedPage Today on MSN
Complement inhibitor slowed kidney decline in IgA nephropathy
Continued FDA approval of iptacopan was contingent on 2-year trial data ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Early-stage startups VFlowTech, Complement 1, ReelSaga, LUZO, ContraVault AI, M1xchange, Rohal Technologies, and Third Bracket have raised funding from various investors in separate rounds, the ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Evidence-based lifestyle modification platform for oncology achieves 90%+ adherence with new dedicated CoActive Coach model, significantly improving cancer-related health outcomes. NEW YORK, May 13, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results